1. Home
  2. SVII vs ABEO Comparison

SVII vs ABEO Comparison

Compare SVII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVII
  • ABEO
  • Stock Information
  • Founded
  • SVII 2021
  • ABEO N/A
  • Country
  • SVII United States
  • ABEO United States
  • Employees
  • SVII N/A
  • ABEO N/A
  • Industry
  • SVII Blank Checks
  • ABEO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SVII Finance
  • ABEO Health Care
  • Exchange
  • SVII Nasdaq
  • ABEO Nasdaq
  • Market Cap
  • SVII 248.9M
  • ABEO 243.9M
  • IPO Year
  • SVII 2022
  • ABEO 1980
  • Fundamental
  • Price
  • SVII $11.30
  • ABEO $6.46
  • Analyst Decision
  • SVII
  • ABEO Strong Buy
  • Analyst Count
  • SVII 0
  • ABEO 3
  • Target Price
  • SVII N/A
  • ABEO $18.00
  • AVG Volume (30 Days)
  • SVII 14.2K
  • ABEO 248.5K
  • Earning Date
  • SVII 01-01-0001
  • ABEO 11-11-2024
  • Dividend Yield
  • SVII N/A
  • ABEO N/A
  • EPS Growth
  • SVII 36.87
  • ABEO N/A
  • EPS
  • SVII 0.37
  • ABEO N/A
  • Revenue
  • SVII N/A
  • ABEO N/A
  • Revenue This Year
  • SVII N/A
  • ABEO N/A
  • Revenue Next Year
  • SVII N/A
  • ABEO $7,097.06
  • P/E Ratio
  • SVII $30.53
  • ABEO N/A
  • Revenue Growth
  • SVII N/A
  • ABEO 147.52
  • 52 Week Low
  • SVII $10.72
  • ABEO $3.05
  • 52 Week High
  • SVII $11.30
  • ABEO $9.01
  • Technical
  • Relative Strength Index (RSI)
  • SVII 81.34
  • ABEO 67.25
  • Support Level
  • SVII $11.20
  • ABEO $6.06
  • Resistance Level
  • SVII $11.23
  • ABEO $6.48
  • Average True Range (ATR)
  • SVII 0.01
  • ABEO 0.33
  • MACD
  • SVII 0.01
  • ABEO 0.05
  • Stochastic Oscillator
  • SVII 100.00
  • ABEO 88.98

About SVII Spring Valley Acquisition Corp. II

Spring Valley Acquisition Corp II is a blank check company.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Share on Social Networks: